rehabilitation methods and the use of serotonin norepinephrine reuptake inhibitors (venlafaxine) in the treatment of patients with persistent postural perceptual dizziness

Comparison of vestibular rehabilitation methods and the use of serotonin norepinephrine reuptake inhibitors (venlafaxine) in the treatment of patients with persistent postural perceptual dizziness.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230803059017N1

Enrollment

Registered

2023-08-07

Start date

2023-08-23

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Persistent postural perceptual dizziness. Dizziness and giddiness

Interventions

Intervention 1: Intervention group: Treatment with venlafaxine dose 37.5 made by Hakim Pharmaceutical Company once a day for 6 weeks. Intervention 2: Intervention group: vestibular rehabilitation once

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Comparison of two vestibular rehabilitation methods and the use of serotonin norepinephrine reuptake inhibitors (venlafaxine) in the treatment of patients with persistent postural perceptual dizziness. Age over 18 years and under 65 years Informed consent to participate in the study Dizziness Handicap Inventory (DHI) >16

Exclusion criteria

Exclusion criteria: Having psychiatric and/or cognitive disorders that prevent understanding tests and questionnaires. Using drugs that cause dizziness Having brain structural disorders Having high blood pressure Having a history of heart disease such as heart failure and heart attack hyperthyroidism

Design outcomes

Primary

Measure	Time frame
Dizziness. Timepoint: before and after treatment (6 weeks later). Method of measurement: dizziness handicap inventory.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNiloofar Tarbiat

Esfahan University of Medical Sciences

niloofar.tarbiat@yahoo.com+98 937 523 4838

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026